Home  |  Contact

Cellosaurus OE19 (CVCL_1622)

[Text version]

Cell line name OE19
Synonyms OE-19; JROECL 19; JROECL19; OEC19
Accession CVCL_1622
Resource Identification Initiative To cite this cell line use: OE19 (RRID:CVCL_1622)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: MD Anderson Cell Lines Project.
Part of: TCGA-110-CL cell line panel.
Characteristics: Contains a 100 fold amplification of ERBB2 (PubMed=15511476).
Doubling time: ~50-60 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Heterozygous for TP53 p.Asn310Lysfs*27 (c.929dup) (c.929_930ins1) (CCLE; Cosmic-CLP).
Genome ancestry Source: PubMed=30894373

Origin% genome
African15.01
Native American0.16
East Asian, North1.83
East Asian, South0
South Asian11.79
European, North8.22
European, South62.99
Disease Esophageal adenocarcinoma (NCIt: C4025)
Adenocarcinoma of the esophagus (ORDO: Orphanet_99976)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Male
Age at sampling 72Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP; DSMZ; ECACC; PubMed=20075370; PubMed=25877200

Markers:
AmelogeninX
CSF1PO11,13
D2S133818,19
D3S135815,18
D5S81811,14
D7S8208
D8S117913,15
D13S3179,11
D16S53912,13
D18S5112 (PubMed=25877200)
12,13 (PubMed=20075370)
D19S43313
D21S1130
FGA23,26
Penta D9
Penta E5,8
TH018,9
TPOX8
vWA16,17 (Cosmic-CLP; ECACC)
16,17,18 (DSMZ; PubMed=20075370; PubMed=25877200)

Run an STR similarity search on this cell line
Web pages http://tcpaportal.org/mclp/
https://www.phe-culturecollections.org.uk/media/115878/oe19-cell-line-profile.pdf
Publications

PubMed=9010035; DOI=10.1038/bjc.1997.42
Rockett J.C., Larkin K., Darnton S.J., Morris A.G., Matthews H.R.
Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization.
Br. J. Cancer 75:258-263(1997)

PubMed=15511476; DOI=10.1016/j.athoracsur.2004.05.037
Dahlberg P.S., Jacobson B.A., Dahal G., Fink J.M., Kratzke R.A., Maddaus M.A., Ferrin L.J.
ERBB2 amplifications in esophageal adenocarcinoma.
Ann. Thorac. Surg. 78:1790-1800(2004)

PubMed=16364037; DOI=10.1111/j.1442-2050.2006.00530.x
Su M., Chin S.-F., Li X.-Y., Edwards P., Caldas C., Fitzgerald R.C.
Comparative genomic hybridization of esophageal adenocarcinoma and squamous cell carcinoma cell lines.
Dis. Esophagus 19:10-14(2006)

PubMed=20075370; DOI=10.1093/jnci/djp499
Boonstra J.J., van Marion R., Beer D.G., Lin L., Chaves P., Ribeiro C., Pereira A.D., Roque L., Darnton S.J., Altorki N.K., Schrump D.S., Klimstra D.S., Tang L.H., Eshleman J.R., Alvarez H., Shimada Y., van Dekken H., Tilanus H.W., Dinjens W.N.M.
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
J. Natl. Cancer Inst. 102:271-274(2010)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=24083764; DOI=10.7314/APJCP.2013.14.8.4891
Li J.-C., Liu D., Yang Y., Wang X.-Y., Pan D.-L., Qiu Z.-D., Su Y., Pan J.-J.
Growth, clonability, and radiation resistance of esophageal carcinoma-derived stem-like cells.
Asian Pac. J. Cancer Prev. 14:4891-4896(2013)

PubMed=25070024; DOI=10.1007/s00423-014-1235-1
Drenckhan A., Grob T., Dupree A., Dohrmann T., Mann O., Izbicki J.R., Gros S.J.
Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.
Langenbecks Arch. Surg. 399:879-888(2014)

PubMed=23795680; DOI=10.1111/dote.12095
Boonstra J.J., Tilanus H.W., Dinjens W.N.M.
Translational research on esophageal adenocarcinoma: from cell line to clinic.
Dis. Esophagus 28:90-96(2015)

PubMed=26512696; DOI=10.3390/cancers7040881
O'Callaghan C., Fanning L.J., Barry O.P.
Hypermethylation of MAPK13 promoter in oesophageal squamous cell carcinoma is associated with loss of p38delta MAPK expression.
Cancers (Basel) 7:2124-2133(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31395879; DOI=10.1038/s41467-019-11415-2
Yu K., Chen B., Aran D., Charalel J., Yau C., Wolf D.M., van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.
Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.
Nat. Commun. 10:3574-3574(2019)

Cross-references
Cell line collections DSMZ; ACC-700
ECACC; 96071721
Cell line databases/resources CLDB; cl3761
CCLE; OE19_OESOPHAGUS
Cell_Model_Passport; SIDM00479
Cosmic-CLP; 910079
DepMap; ACH-000679
IGRhCellID; OE19
LINCS_LDP; LCL-1796
Ontologies CLO; CLO_0008238
EFO; EFO_0002308
Biological sample resources BioSample; SAMN03471032
BioSample; SAMN10988362
Chemistry resources ChEMBL-Cells; CHEMBL3308462
ChEMBL-Targets; CHEMBL1075555
GDSC; 910079
PharmacoDB; OE19_1194_2019
Gene expression databases ArrayExpress; E-MTAB-38
ArrayExpress; E-MTAB-783
ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
GEO; GSM827301
GEO; GSM887475
GEO; GSM888555
GEO; GSM1264050
GEO; GSM1264051
GEO; GSM1264052
GEO; GSM1264053
GEO; GSM1264054
GEO; GSM1264092
GEO; GSM1264093
GEO; GSM1264094
GEO; GSM1264095
GEO; GSM1264096
GEO; GSM1670302
Other Wikidata; Q54931862
Polymorphism and mutation databases Cosmic; 871232
Cosmic; 910079
Cosmic; 978854
Cosmic; 997860
Cosmic; 1175878
Cosmic; 1599342
Cosmic; 1618819
Cosmic; 1995600
IARC_TP53; 21600
LiGeA; CCLE_923
Progenetix; CVCL_1622
Entry history
Entry creation04-Apr-2012
Last entry update29-Oct-2020
Version number31